Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
Muggia FM, Hainsworth JD, Jeffers S, Miller P, Groshen S, Tan M, Roman L, Uziely B, Muderspach L, Garcia A, Burnett A, Greco FA, Morrow CP, Paradiso LJ, Liang LJ.
Muggia FM, et al. Among authors: morrow cp.
J Clin Oncol. 1997 Mar;15(3):987-93. doi: 10.1200/JCO.1997.15.3.987.
J Clin Oncol. 1997.
PMID: 9060537
Clinical Trial.